A Guide to Weight Loss Injections. Everything you need to know, including how to minimise side effects and maximise your chance of success
Par :Formats :
Actuellement indisponible
Cet article est actuellement indisponible, il ne peut pas être commandé sur notre site pour le moment. Nous vous invitons à vous inscrire à l'alerte disponibilité, vous recevrez un e-mail dès que cet ouvrage sera à nouveau disponible.
Disponible dans votre compte client Decitre ou Furet du Nord dès validation de votre commande. Le format ePub protégé est :
- Compatible avec une lecture sur My Vivlio (smartphone, tablette, ordinateur)
- Compatible avec une lecture sur liseuses Vivlio
- Pour les liseuses autres que Vivlio, vous devez utiliser le logiciel Adobe Digital Edition. Non compatible avec la lecture sur les liseuses Kindle, Remarkable et Sony
- Non compatible avec un achat hors France métropolitaine
, qui est-ce ?Notre partenaire de plateforme de lecture numérique où vous retrouverez l'ensemble de vos ebooks gratuitement
Pour en savoir plus sur nos ebooks, consultez notre aide en ligne ici
C'est si simple ! Lisez votre ebook avec l'app Vivlio sur votre tablette, mobile ou ordinateur :
- Nombre de pages224
- FormatePub
- ISBN978-1-0354-3043-7
- EAN9781035430437
- Date de parution01/01/2026
- Protection num.Adobe DRM
- Infos supplémentairesepub
- ÉditeurHeadline Home
Résumé
Health experts believe that a new class of drugs known as GLP-1s, better known as weight loss injections such as Ozempic, Wegovy and Mounjaro, have a significant role to play in transforming people's health and reducing obesity rates in the UK and worldwide. In this book, Dr David Cavan, a world-leading authority on all aspects of diabetes and the use of semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro), reviews the history, development, safe use of, benefits and risks of the latest generation of this class of important medications.
The book focuses on Wegovy, which is approved for use in the NHS, alongside diet and physical activity, to manage excess weight and obesity; Ozempic, which is used to treat type 2 diabetes; and Mounjaro (tirzepatide) which is now approved by the Medicines and Healthcare products Regulatory Agency (MHRA) for weight loss management by the NHS. Up to date with a rigorous understanding of both the latest scientific research and public health policy and informed by years of clinical experience, this guide is rich in detail and patient experience.
Dr Cavan gives the reader all the facts - so they are in the best possible position to make sensible decisions that help them to discuss with their doctor and achieve their health goals.
The book focuses on Wegovy, which is approved for use in the NHS, alongside diet and physical activity, to manage excess weight and obesity; Ozempic, which is used to treat type 2 diabetes; and Mounjaro (tirzepatide) which is now approved by the Medicines and Healthcare products Regulatory Agency (MHRA) for weight loss management by the NHS. Up to date with a rigorous understanding of both the latest scientific research and public health policy and informed by years of clinical experience, this guide is rich in detail and patient experience.
Dr Cavan gives the reader all the facts - so they are in the best possible position to make sensible decisions that help them to discuss with their doctor and achieve their health goals.
Health experts believe that a new class of drugs known as GLP-1s, better known as weight loss injections such as Ozempic, Wegovy and Mounjaro, have a significant role to play in transforming people's health and reducing obesity rates in the UK and worldwide. In this book, Dr David Cavan, a world-leading authority on all aspects of diabetes and the use of semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro), reviews the history, development, safe use of, benefits and risks of the latest generation of this class of important medications.
The book focuses on Wegovy, which is approved for use in the NHS, alongside diet and physical activity, to manage excess weight and obesity; Ozempic, which is used to treat type 2 diabetes; and Mounjaro (tirzepatide) which is now approved by the Medicines and Healthcare products Regulatory Agency (MHRA) for weight loss management by the NHS. Up to date with a rigorous understanding of both the latest scientific research and public health policy and informed by years of clinical experience, this guide is rich in detail and patient experience.
Dr Cavan gives the reader all the facts - so they are in the best possible position to make sensible decisions that help them to discuss with their doctor and achieve their health goals.
The book focuses on Wegovy, which is approved for use in the NHS, alongside diet and physical activity, to manage excess weight and obesity; Ozempic, which is used to treat type 2 diabetes; and Mounjaro (tirzepatide) which is now approved by the Medicines and Healthcare products Regulatory Agency (MHRA) for weight loss management by the NHS. Up to date with a rigorous understanding of both the latest scientific research and public health policy and informed by years of clinical experience, this guide is rich in detail and patient experience.
Dr Cavan gives the reader all the facts - so they are in the best possible position to make sensible decisions that help them to discuss with their doctor and achieve their health goals.
